• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

    10/1/25 8:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care
    Get the next $PFSA alert in real time by email

    Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France

    BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces additional growth in its customer base in Europe, with a collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI). Under the agreement, Pr. Gouëffic will adopt Lumee™ oxygen monitoring technology in his practice and in clinical studies that advance application of Lumee for home monitoring. Pr. Gouëffic and his associated practices account for approximately 8% of all CLTI cases in France.

    "My practice, in addition to those of my affiliates, treats a meaningful number of CLTI cases in France and I believe Profusa's Lumee technology to be a game changer in our patient care program and a true advancement clinical disease governance," said Pr. Gouëffic. "Real-time oxygen monitoring data for patients suffering from CLTI, while critical during surgery, is equally as important during recovery at home. Given the large clinical need, I believe offering Lumee to our patients will result in improved outcomes."

    Pr. Gouëffic has more than 20 years of experience in endovascular and open procedures for peripheral arterial diseases, specializing in lower limb arterial disease, endovascular revascularization, wound healing, and amputation prevention. In addition, Pr. Gouëffic has served as principal investigator for numerous clinical trials that advanced the management of lower limb peripheral artery disease and has authored more than 140 articles in peer-reviewed journals.   Pr. Gouëffic is the current president of the French academic association for clinical research and the coordinator of the FRANCE-PAD network of 6 high volume hospitals that account for approximately 8% of lower limb peripheral artery disease treatment volumes in France.

    "Our Lumee oxygen monitoring system continues to be validated with the steady addition of new surgeon customers to our network. We warmly welcome Pr. Gouëffic and look forward to advancing vascular disease management with our commercial and clinical collaboration," said Ben Hwang, Ph.D., Profusa's Chairman and CEO. "We are also excited to serve Pr. Gouëffic's affiliates, which all combined, account for approximately 8% of CLTI cases in France. We believe we provide a differentiated, real time biochemistry monitoring platform technology for use at the clinic and at home, and are focused on serving a large endovascular market need, estimated at over 300,000 procedures a year in Europe."

    About Profusa

    Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

    "LUMEE", "PROFUSA" and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

    For more information, visit https://profusa.com.

    Special Note Regarding Forward-Looking Statements

    Certain statements in this press release (this "Press Release") may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "propose," "seek," "should," "strive," "will," or "would" or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

    Contacts

    Investor and Media Contacts

    email: [email protected]

    phone: 1 (212) 655-0924



    Primary Logo

    Get the next $PFSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

    Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces additional growth in its customer base in Europe, with a collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI). Under the agreement, Pr. Gouëffic will a

    10/1/25 8:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

    Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows BERKELEY, Calif, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces the adoption of NVIDIA technology to power an AI-driven insight portal for continuous biochemistry monitoring.  "We believe that real-time biochemistry data across a large population is a data-set that is currently missing to enable the fulfillment of the promise

    9/11/25 8:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    SEC Filings

    View All

    SEC Form EFFECT filed by Profusa Inc.

    EFFECT - Profusa, Inc. (0001859807) (Filer)

    9/29/25 12:15:23 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Profusa Inc.

    424B3 - Profusa, Inc. (0001859807) (Filer)

    9/26/25 4:53:34 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Profusa Inc.

    DEF 14A - Profusa, Inc. (0001859807) (Filer)

    9/23/25 11:21:02 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Leadership Updates

    Live Leadership Updates

    View All

    Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

    Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont Berkeley, Calif, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces two major leadership additions as of the close of the business combination with NorthView Acquisition Corp (NVAC).  Peter O'Rourke, former Acting U.S. Secretary of Veterans Affair

    8/19/25 8:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Financials

    Live finance-specific insights

    View All

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology